Search results: Sage Journals

Restricted accessResearch articleFirst published August, 2016

Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2,3-Dioxygenase

Rajni Sharma, Giulia Di Dalmazi, Patrizio Caturegli

Thyroid®

Restricted accessResearch articleFirst published December, 2021

Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model

Silvia Ippolito, Giulia Di Dalmazi, Fabiana Pani [...]

Thyroid®

Open accessReview articleFirst published 2023

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition

Firas Y. Kreidieh, Hussein A. Tawbi

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published February, 2022

Increased Risk of Thyroid Dysfunction with Combination PD-1 and CTLA-4 Blockade,Even in the Absence of Positive Thyroid Antibodies

Anupam Kotwal

Clinical Thyroidology®

Open accessResearch articleFirst published 2024

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Young Kwang Chae, Megan Othus, Sandip Pravin Patel [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2024

Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm,prospective phase II trial

Heqi Yang, Linjuan Li, Xiaofen Li [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published December, 2003

CTLA-4 AT-Repeat Polymorphism Reduces the Inhibitory Function of CTLA-4 in Graves' Disease

Masaki Takara, Tsuyoshi Kouki, Leslie J. DeGroot

Thyroid®

Open accessCorrectionFirst published 2025

Corrigendum to “Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm,prospective phase II trial”

Therapeutic Advances in Medical Oncology

Restricted accessReview articleFirst published January, 2017

Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant

Rimda Wanchoo, Leonardo V. Riella, Nupur N. Uppal [...]

Journal of Onco-Nephrology

Restricted accessResearch articleFirst published March, 2010

HIV-Specific TGF- β -Positive CD4 + T Cells Do Not Express Regulatory Surface Markers and Are Regulated by CTLA-4

Mohamed Elrefaei, Candace M. Burke, Chris A.R. Baker [...]

AIDS Research and Human Retroviruses

Restricted accessResearch articleFirst published August, 2016

Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2,3-Dioxygenase

Rajni Sharma, Giulia Di Dalmazi, Patrizio Caturegli

Thyroid®

Restricted accessResearch articleFirst published December, 2021

Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model

Silvia Ippolito, Giulia Di Dalmazi, Fabiana Pani [...]

Thyroid®

Open accessReview articleFirst published 2023

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition

Firas Y. Kreidieh, Hussein A. Tawbi

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published February, 2022

Increased Risk of Thyroid Dysfunction with Combination PD-1 and CTLA-4 Blockade,Even in the Absence of Positive Thyroid Antibodies

Anupam Kotwal

Clinical Thyroidology®

Open accessResearch articleFirst published 2024

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Young Kwang Chae, Megan Othus, Sandip Pravin Patel [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2024

Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm,prospective phase II trial

Heqi Yang, Linjuan Li, Xiaofen Li [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published December, 2003

CTLA-4 AT-Repeat Polymorphism Reduces the Inhibitory Function of CTLA-4 in Graves' Disease

Masaki Takara, Tsuyoshi Kouki, Leslie J. DeGroot

Thyroid®

Open accessCorrectionFirst published 2025

Corrigendum to “Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm,prospective phase II trial”

Therapeutic Advances in Medical Oncology

Restricted accessReview articleFirst published January, 2017

Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant

Rimda Wanchoo, Leonardo V. Riella, Nupur N. Uppal [...]

Journal of Onco-Nephrology

Restricted accessResearch articleFirst published March, 2010

HIV-Specific TGF- β -Positive CD4 + T Cells Do Not Express Regulatory Surface Markers and Are Regulated by CTLA-4

Mohamed Elrefaei, Candace M. Burke, Chris A.R. Baker [...]

AIDS Research and Human Retroviruses